Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Abscess Collections: Antibiotics or Steroids?
Dias PR, Bolt L, Iking-Konert C, Arrigo M, Huber LC. Dias PR, et al. Among authors: iking konert c. Case Reports Immunol. 2024 Jan 25;2024:3671685. doi: 10.1155/2024/3671685. eCollection 2024. Case Reports Immunol. 2024. PMID: 38304552 Free PMC article.
ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
Iking-Konert C, von Hinüber U, Richter C, Schwenke H, Gürtler I, Kästner P, Klapperich B, Peters MA, Burmester GR. Iking-Konert C, et al. Rheumatology (Oxford). 2016 Apr;55(4):624-35. doi: 10.1093/rheumatology/kev372. Epub 2015 Oct 29. Rheumatology (Oxford). 2016. PMID: 26515959
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].
Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T. Proft F, et al. Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. Z Rheumatol. 2018. PMID: 28589389 German.
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].
Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K. Fiehn C, et al. Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Z Rheumatol. 2018. PMID: 29968101 Review. German.
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP. Dörner T, et al. Clin Exp Rheumatol. 2019 Nov-Dec;37(6):937-945. Epub 2019 Apr 16. Clin Exp Rheumatol. 2019. PMID: 31025930 Free article. Clinical Trial.
94 results